0 CHECKOUT

In Vitro Fertilization (IVF) Asia-Pacific Market - Opportunities and Forecasts, 2014 - 2020

  • ID: 3766376
  • March 2016
  • Region: Asia Pacific
  • 124 pages
  • Allied Analytics LLP
1 of 5
Asia-Pacific In Vitro Fertilization Market is Expected to Reach $4,021.3 million, by 2021

FEATURED COMPANIES

  • Auxogyn Inc.
  • Cook Medicals
  • Cooper Surgical. Inc.
  • EMD Serono Inc.
  • Genea Biomedx
  • Irvine Scientific Inc.
  • MORE



In-vitro fertilization is a type of assisted reproductive technology that helps women in conceiving. The Asia Pacific embryo transfer market, valued at $1.9 billion in 2014, is estimated to reach $3.5 billion by 2020. Delayed pregnancy in women is one of the major driving factors of the embryo transfer market, as the chances of conceiving lowers with age. The success rate of getting pregnant with embryo transfer technique is higher in the age group of 35-39. Other driving factors of the embryo transfer market are rise in infertility rate due to rise in stress levels, change in life style and fertility related diseases. Globally, around 15% of the couples faces infertility issues in which males contribute to 20-30% of the overall cases.

The major limiting factors of this market are the cost involved and lower success rates in the treatment. Patients may not conceive in the first cycle of embryo transfer procedure. Patients have to undergo many cycles to achieve pregnancy, and this adds to the overall cost. The average cost of this procedure is approximately $3,000- $8,000. This acts as a major limitation, in adoption of the technique, for people with low income. Another READ MORE >

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Auxogyn Inc.
  • Cook Medicals
  • Cooper Surgical. Inc.
  • EMD Serono Inc.
  • Genea Biomedx
  • Irvine Scientific Inc.
  • MORE

Chapter: 1 INTRODUCTION

1.1 Report Description
1.2 Key Take Away
1.3 Market Segmentation
1.4 Research Methodology

1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Analyst Tools and Models

Chapter: 2 EXECUTIVE SUMMARY



Chapter: 3 MARKET OVERVIEW

3.1 Market Definition and Scope
3.2 Key Intelligence

3.2.1 Impact Analysis
3.2.2 Market Attractiveness Analysis

3.2.2.1 Asia-Pacific IVF Market by End-Users
3.2.2.2 Asia-Pacific IVF Market, Country wise analysis

3.3 Strategic Management Insights

3.3.1 Value Chain Analysis

3.4 IVF Pricing Trends by Country
3.5 IVF Cycles by Country
3.6 Asia-Pacific IVF Market by End Users
3.7 Market Dynamics

3.7.1 Drivers

3.7.1.1 Delayed pregnancies in women
3.7.1.2 Rise in global infertility rates
3.7.1.3 Emergence of new fertility tourism destinations

3.7.2 Restraints

3.7.2.1 Cost involved in the treatment
3.7.2.2 Low level of awareness in developing economies
3.7.2.3 Inadequate reimbursements policies for IVF treatments
3.7.2.4 Ethical Considerations

3.7.3 Opportunities

3.7.3.1 Market growth by relaxing the legal considerations
3.7.3.2 New technology development and treatment options
3.7.3.3 Three-parent IVF

3.8 Key Findings

Chapter: 4 REVENUE AND NUMBER OF CYCLES

4.1 India IVF Market (Revenue and Number of Cycles)

4.1.1 Number Of IVF Cycles, 2014-2020
4.1.2 India IVF Market, 2014-2020 ($Million)

4.2 India IVF Market by End Users

4.2.1 Market Dynamics

4.2.1.1 Drivers
4.2.1.2 Restraints

4.2.2 Regulatory Issues, Legislations and Authorities
4.2.3 Insurance Reimbursement Scenario
4.2.4 Profiles of Major Players

4.2.4.1 Sun Pharmaceutical Industries Ltd.
4.2.4.2 Trivector Origio Scientific Pvt. Ltd
4.2.4.3 Lab IVF Asia Pte. Ltd
4.2.4.4 LG Life Sciences.
4.2.4.5 Cadila Healthcare Ltd.( Zydus Cadila Group)
4.2.4.6 Bourn Hall Clinic
4.2.4.7 Southend Fertility And IVF Centre
4.2.4.8 Morpheus IVF Fertility Center
4.2.4.9 Bloom Fertility Center
4.2.4.10 Manipal Ankur
4.2.4.11 Cloudnine
4.2.4.12 Nova IVI Fertility

4.3 China IVF Market (Revenue and Number of Cycles)

4.3.1 Number of IVF Cycles, 2014-2020
4.3.2 China IVF Market, 2014-2020 ($Million)

4.4 China IVF Market by End User

4.4.1 Market Dynamics

4.4.1.1 Drivers

4.4.1.1.1 EMOTIONAL REASONS
4.4.1.1.2 INCREASED RATE OF INFERTILITY
4.4.1.1.3 CHANGE IN LIFESTYLE

4.4.1.2 Restraints

4.4.1.2.1 COST OF LIVING
4.4.1.2.2 ONE CHILD POLICY

4.4.2 Regulatory Issues, Legislations and Authorities
4.4.3 Insurance Reimbursement Scenario
4.4.4 Company Profile

4.4.4.1 Cook Medical, Inc.
4.4.4.2 Vitrolife AB
4.4.4.3 Reproductive And Genetic Hospital Citic-Xiangya
4.4.4.4 Shenyang Hospital
4.4.4.5 Shandong Provincial Hospital
4.4.4.6 Centre For Reproductive Medicine

4.5 Japan IVF Market (Revenue and Number of Cycles)

4.5.1 Number of IVF Cycles, 2014-2020
4.5.2 Japan IVF Market, 2014-2020 ($Million)

4.6 Japan IVF Market by End-Users

4.6.1 Market Dynamics

4.6.1.1 Drivers
4.6.1.2 Restraints

4.6.2 Regulatory Issues, Legislations and Authorities
4.6.3 Insurance Reimbursement Scenario
4.6.4 Company Profile

4.6.4.1 EMD Serono, Inc.
4.6.4.2 IVF NAMBA Clinic
4.6.4.3 Iwaki Womens Clinic
4.6.4.4 Sanno Hospital

4.7 Australia IVF Market (Revenue and Number of Cycles)

4.7.1 Number of IVF Cycles, 2014-2020
4.7.2 Australia IVF Market, 2014-2020 ($Million)

4.8 Australia IVF Market by End Users

4.8.1 Market Dynamics

4.8.1.1 Drivers
4.8.1.2 Restraints

4.8.1.2.1 EMOTIONAL AND PHYSICAL STRESS
4.8.1.2.2 NO GUARANTEE
4.8.1.2.3 SURPLUS EMBRYOS

4.8.2 Regulatory Issues, Legislations and Authorities
4.8.3 Insurance Reimbursement Scenario
4.8.4 Company Profile

4.8.4.1 Genea Biomedx
4.8.4.2 Thermo Fisher Scientific Inc.
4.8.4.3 Virtus Health
4.8.4.4 Monash IVF
4.8.4.5 City Fertility
4.8.4.6 Flinders Fertility

4.9 New Zealand IVF Market (Revenue and Number of Cycles)

4.9.1 Number of IVF Cycles, 2014-2020
4.9.2 New Zealand IVF Market, 2014-2020 ($Million)

4.10 New Zealand IVF Market by End Users

4.10.1 Market Dynamics

4.10.1.1 Drivers
4.10.1.2 Restraints

4.10.2 Regulatory Issues, Legislations and Authorities
4.10.3 Insurance Reimbursement Scenario
4.10.4 Company Profiles

4.10.4.1 Fertility Associates
4.10.4.2 Fertility Plus
4.10.4.3 Repromed

4.11 Korea IVF Market (Revenue and Number of Cycles)

4.11.1 Number of IVF Cycles, 2014-2020
4.11.2 Korea IVF Market, 2014-2020 ($Million)

4.12 Korea IVF Market by End Users

4.12.1 Market Dynamics

4.12.1.1 Drivers
4.12.1.2 Restraints

4.12.2 Regulatory Issues, Legislations and Authorities
4.12.3 Insurance Reimbursement Scenario
4.12.4 Company Profiles

4.12.4.1 Cha General Hospital
4.12.4.2 MARIA Fertility Hospital

4.13 Thailand IVF Market (Revenue and Number of Cycles)

4.13.1 Number Of IVF Cycles, 2014-2020
4.13.2 Thailand IVF Market, 2014-2020 ($Million)

4.14 Thailand IVF Market by End Users

4.14.1 Market Dynamics

4.14.1.1 Drivers

4.14.1.1.1 GOVERNMENT INITIATIVES
4.14.1.1.2 ECONOMICAL CONSIDERATIONS
4.14.1.1.3 BOOST IN MEDICAL TOURISM

4.14.1.2 Restraints

4.14.1.2.1 COMPARATIVELY LOW SUCCESS RATE
4.14.1.2.2 ETHICAL ISSUES IN ALLOWING GENDER SELECTION

4.14.2 Regulatory Issues, Legislations and Authorities
4.14.3 Insurance Reimbursement Scenario
4.14.4 Company Profiles

4.14.4.1 Bangkok Fertility Center
4.14.4.2 Siriraj Hospital
4.14.4.3 Ramathibodi Hospital
4.14.4.4 Perfect Woman Institute
4.14.4.5 Jetanin Institute for Assisted Reproduction

4.15 Other Asia-Pacific IVF Market (Revenue And Number Of Cycles)

4.15.1 Number of IVF Cycles, 2014-2020
4.15.2 Other Asia-Pacific IVF Market, 2014-2020 ($Million)

4.16 Other Asia-Pacific IVF Market by End Users

4.16.1 Market Dynamics

4.16.1.1 Drivers

4.16.1.1.1 INCREASE IN DISPOSABLE INCOME
4.16.1.1.2 ADVANCES IN IVF TECHNOLOGY
4.16.1.1.3 DECLINE IN FERTILITY RATES

4.16.1.2 Restraints

4.16.1.2.1 PHYSICAL AND EMOTIONAL IMPACT DUE TO LOW SUCCESS RATE

4.16.2 Regulatory Issues, Legislations and Authorities
4.16.3 Insurance Reimbursement Scenario
4.16.4 Company Profiles

4.16.4.1 Fertility Centre, Siloam Hospitals Surabana
4.16.4.2 CRM-MIA-Philippines
4.16.4.3 IVFAS

List of Figures

Fig. 1 Asia-Pacific IVF Market Attractiveness Analysis by End-Users, (2014-2020)
Fig. 2 Asia-Pacific IVF Market Attractiveness Analysis by Countries, (2014-2020)
Fig. 3 Value Chain Of Asia-Pacific IVF Market
Fig. 4 Asia-Pacific IVF Market, 2014-2020 ($Million)
Fig. 5 Number Of Asia-Pacific IVF Cycles, 2014-2020 (Thousand)
Fig. 6 Total Fertility Rate ( Children Born/ Women)
Fig. 7 China Fertility Rate (Children Born/Women)
Fig. 8 Total Fertility Rate (Children Born/ Women)
Fig. 9 Total Fertility Rate ( Children Born/ Women)
Fig. 10 IVF Success Rate For Australia
Fig. 11 Total Fertility Rate (Children Born/ Women)
Fig. 12 Total Fertility Rate (Children Born/Women) - South Korea
Fig. 13 Thailand Fertility Rate Child Born/Women

List of Tables

Table 1 Pricing Trends By Country, 2014
Table 2 Number Of IVF Cycles By Countries, 2014-2020 (Thousand)
Table 3 Asia-Pacific IVF Cycles By End User, 2014-2020 (Thousand)
Table 4 Asia-Pacific IVF Revenue By End User, 2014-2020 ($Million)
Table 5 IVF Success Rates According To Age
Table 6 Number Of IVF Cycles, Asia-Pacific, 2014-2020 (Thousand)
Table 7 Asia-Pacific IVF Market 2014-2020 ($Million)
Table 8 Number Of IVF Cycles, India, 2014-2020 (Thousand)
Table 9 India IVF Market 2014-2020 ($Million)
Table 10 India IVF Cycles By End Users, 2014-2020 (Thousand)
Table 11 India IVF Market Revenue By End Users, 2014-2020 ($Million)
Table 12 Sun Pharmaceutical Business Overview
Table 13 Snapshot Of Sun Pharmaceutical
Table 14 Trivector Origio Scientific Business Overview
Table 15 Snapshot Of Trivector Origio
Table 16 Lab IVF Asia Business Overview
Table 17 Snapshot Of Lab IVF Asia
Table 18 LG Life Science Business Overview
Table 19 Snapshot Of LG Life Science
Table 20 Cadila Health Care Business Overview
Table 21 Snapshot Of Cadila Health Care
Table 22 Bourn Hall Business Overview
Table 23 Southend Fertility And IVF Centre Business Overview
Table 24 Morpheus IVF Fertility Center Business Overview
Table 25 Bloom Fertility Center Business Overview
Table 26 Manipal Ankur Business Overview
Table 27 Cloudnine Business Overview
Table 28 Nova IVI Fertility Business Overview
Table 29 Number Of IVF Cycles, China, 2014-2020 (Thousand)
Table 30 China IVF Market 2014-2020 ($Million)
Table 31 China IVF Cycles By End Users, 2014-2020 (Thousand)
Table 32 China IVF Market Revenue By End Users, 2014-2020 ($Million)
Table 33 Cook Medical Inc Business Overview
Table 34 Snapshot Of Cook Medical Inc.
Table 35 Vitrolife Ab, Business Overview
Table 36 Snapshot Of Vitrolife Ab
Table 37 Reproductive And Genetic Hospital Citic-Xiangya, Business Overview
Table 38 Shenyang Hospital Business Overview
Table 39 Shandong Provincial Hospital Business Overview
Table 40 Centre For Reproductive Medicine, Business Overview
Table 41 Number Of IVF Cycles, Japan, 2014-2020 (Thousand)
Table 42 Japan IVF Market 20142021 ($Million)
Table 43 Japan IVF Cycles By End Users, 2014-2020 (Thousand)
Table 44 Japan IVF Market Revenue By End Users, 2014-2020 ($Million)
Table 45 Emd Serono Inc Business Overview
Table 46 Snapshot Of Emd Serono Inc.
Table 47 IVF Namba Clinic Business Overview
Table 48 Iwaki Womens Clinic Business Overview
Table 49 Sanno Hospital Business Overview
Table 50 Number Of IVF Cycles, Australia, 2014-2020 (Thousand)
Table 51 Australia IVF Market 2014-2020 ($Million)
Table 52 Outcomes Of Cycles Of IVF By Womens Age Group, 2011
Table 53 Australia IVF Cycles By End Users, 2014-2020 (Thousand)
Table 54 Australia IVF Market Revenue By End Users, 2014-2020 ($Million)
Table 55 Genea Biomedx Technologies Business Overview
Table 56 Snapshot Of Genea Biomedx Technologies
Table 57 Thermo Fisher Scientific Inc. Business Overview
Table 58 Snapshot Of Thermo Fisher Scientific Inc.
Table 59 Vitrus Health Business Overview
Table 60 Monash IVF Business Overview
Table 61 City Fertility Business Overview
Table 62 Flinders Fertility Business Overview
Table 63 Number Of IVF Cycles, New Zealand, 2014-2020 (Thousand)
Table 64 New Zealand IVF Market 20142021 ($Million)
Table 65 New Zealand IVF Revenue By End Users, 2014-2020 ($Million)
Table 66 New Zealand IVF Cycles By End Users, 2014-2020 (Thousand)
Table 67 Fertility Associates Business Overview
Table 68 Fertility Plus Business Overview
Table 69 Repromed Business Overview
Table 70 Number Of IVF Cycles, Korea, 2014-2020 (Thousand)
Table 71 New Zealand IVF Market 2014-2020 ($Million)
Table 72 Korea IVF Market Revenue By End Users, 2014-2020 ($Million)
Table 73 Korea IVF Cycles By End Users, 2014-2020 (Thousand)
Table 74 Cha General Hospital Business Overview
Table 75 Maria Fertility Hospital Business Overview
Table 76 Number Of IVF Cycles, Thailand, 2014-2020 (Thousand)
Table 77 Thailand IVF Market 20142021 ($Million)
Table 78 Thailand IVF Market Revenue By End Users, 2014-2020 ($Million)
Table 79 Thailand IVF Cycles By End Users, 2014-2020 (Thousand)
Table 80 Bangkok Fertility Center Business Overview
Table 81 Siriraj Hospital Business Overview
Table 82 Ramathibodi Hospital Business Overview
Table 83 Perfect Woman Institute Business Overview
Table 84 Jetanin Institute For Assisted Reproduction Business Overview
Table 85 Number Of IVF Cycles, Other Asia-Pacific, 2014-2020 (Thousand)
Table 86 Other Asia-Pacific IVF Market 2014-2020 ($Million)
Table 87 Other Asia-Pacific IVF Market Revenue By End Users, 2014-2020 ($Million)
Table 88 Other Asia-Pacific IVF Cycles By End Users, 2014-2020 (Thousand)
Table 89 Fertility Centre, Siloam Hospitals Surabana Business Overview
Table 90 Crm-Mia-Philippines Business Overview
Table 91 IVF as Business Overview

Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Auxogyn Inc.
  • Cook Medicals
  • Cooper Surgical. Inc.
  • EMD Serono Inc.
  • Genea Biomedx
  • Irvine Scientific Inc.
  • MORE

A new report titled, "In Vitro Fertilization (IVF) Asia-Pacific Market", forecasts the in vitro fertilization market in Asia-Pacific to reach $4,021.3 million by 2021. China would continue to lead the market throughout forecast period with revenue of $1,273.9 million in 2021. However, India is projected to register the highest growth during 2015-2021, both in terms of cycles and revenue.

IVF procedures have emerged as a preferable choice for the fertility treatment in Asia-Pacific. Factors, such as the delayed pregnancies due professional commitments, rise in lifestyle driven infertility, growing trends towards financial stability, and emergence of new fertility tourism destinations is largely contributing to the growth of the Asia-Pacific IVF market. However, factors such as high costs, ethical and religious considerations, inadequate IVF reimbursements are likely to restrain the market growth.

The average age of parenthood in the region has sharply inclined over the last decade. Over two thirds of babies in the region are born to a father over the age of 30 years and about 45% of women conceive at age of 30 years and above, for the first time. The stats are even worse in countries such as Japan, Korea, Singapore and Australia. The growing aging population has been the major concern for government in most of the countries in the region. Countries such as Indonesia, Vietnam, Cambodia and Philippines have fertility rates in excess of 2; however, they are keen to boost their fertility rates to counter the large aging population. Indonesia in particular has a fertility rate of 2.1 but has 210 million people within geriatric age. Korea, which has fertility rate of 1.4, has announced financial support for infertility treatment while Singapore with fertility rate of 1.3 has increased the subsidies for treatment to 75% of the treatment cost. All these have been instrumental in driving the growth of IVF market in Asia Pacific. It is expected that, in 2021, over 1.5 million IVF cycles would be performed in Asia Pacific.

The fertility treatment providers such as fertility clinics, hospitals and surgical centers are invariably competing to gain the edge in the ever growing market. Fertility clinics and hospitals had collectively contributed about 80% of the Asia-Pacific IVF market revenue in 2014, owing to their sophisticated and highly advanced treatments. Moreover, specialized fertility clinics have grown in numbers recently with growing patient preference. As a result, the fertility clinic segment has consolidate its revenue share and would continue to do so over the forecast period.

India and China would emerge as key fertility tourism destinations during the forecast period, largely due to factors such as favorable government regulations, availability of skilled workforce and economical pricing of hospital services compared to other global fertility-treatment destinations. The considerable growth in these countries would be supplemented by the increased rate of infertilities, practices of donor egg IVF cycles, and embryo banking.

Key findings of the study
- India, China and Japan had collectively accounted for about 80% of the total cycles performed in 2014
- In India, the fertility clinics and hospitals segment had collectively accounted for about 82% of the revenue generated in 2014
- China generated largest revenue in 2014
- The IVF market in India is expected to register a promising CAGR of 13.2% during 20152021 in terms of number of cycles performed

Note: Product cover images may vary from those shown
4 of 5

- Auxogyn Inc.
- Cook Medicals
- Cooper Surgical. Inc.
- EMD Serono Inc.
- Genea Biomedx
- Irvine Scientific Inc.
- Ovascience Inc.
- Oxford Gene Technology
- Thermo Fisher Scientific
- Vitrolife AB

Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Actavis
  • Smith & Nephew PLC.
  • Bayer AG
  • Hologic Inc.
  • Abbott Laboratories Ltd.
  • Polpharma SA